CNBC's Jim Cramer on Thursday told investors why he thinks the stock of Johnson & Johnson is performing well this year even as the broader healthcare sector lags.

"With so much momentum, but still a reasonable valuation, I think J&J can keep running, maybe for a while," he said. "The next target is the company's early 2022 all-time high of $186 and change, within sight, up less than ten bucks from here. After that? I say it could go through $200."

Johnson & Johnson's stock has been weighed down for years by lawsuits related to its talc products — so Cramer suggested it might be a surprise to some that the company has been able to "defy the gravitational pull of this health care bear market." Shares are currently up more than 23% year-to-date.

While Cramer said Johnson & Jo

See Full Page